As per SNS Insider, the Global Lung Cancer Liquid Biopsy Market is projected to reach USD 3,947.60 million by 2035, growing at a 13.2% CAGR, while the U.S. market is projected to reach USD 1,472.10 million, advancing at 12.8% CAGR, as expanding regulatory endorsement and insurance coverage drive adoption of non-invasive genomic profiling.

Austin, Texas, Sept. 18, 2026 (GLOBE NEWSWIRE) -- The global Lung Cancer Liquid Biopsy Market was valued at USD 1,142.60 million in 2025 and is projected to reach USD 3,947.60 million by 2035, registering a CAGR of 13.2% during 2026–2035. Growth is driven by growing regulatory approval for genomic testing in the blood, growing insurance coverage, and growing utilization of liquid biopsy technology by pharmaceutical companies to monitor the response to targeted or immune therapies. Further development of minimal residual disease detection, next-generation sequencing panels, and fragmentomics testing will contribute to growth in minimally invasive diagnostic applications within the treatment pathways for lung cancer.


Download the Lung Cancer Liquid Biopsy Market Sample Report: https://www.snsinsider.com/sample-request/11051

The U.S. Lung Cancer Liquid Biopsy Market was valued at approximately USD 441.40 million in 2025 and is projected to reach approximately USD 1,472.10 million by 2035, registering a CAGR of approximately 12.8% during 2026–2035. The factors contributing to the market growth include Medicare decisions, concentration of major liquid biopsy test providers, increased FDA interest, and physicians’ as well as patients’ preferences for blood tests over repeated tissue biopsies. In addition, pharmaceutical trials as well as hospitals' development of sequencing capabilities will ensure consistent domestic penetration of the market.

Why this Market is Gaining Attention in 2026

Regulatory Endorsement and Reimbursement Coverage Are Expanding Clinical Adoption of Blood-Based Genomic Profiling

Liquid biopsy for lung cancer is becoming more relevant clinically as regulatory agencies, clinical practice guidelines, and health insurance providers become aware of the potential use of blood-based genomic tests as a substitute in situations where tissue biopsy is either impractical or not possible. The ability to detect actionable mutations, select treatments, and monitor any molecular changes through non-invasive blood draws allows liquid biopsy to help doctors better understand patients' conditions and needs.

Commercial Findings from the Lung Cancer Liquid Biopsy Market

ctDNA Dominated While Exosomes and Extracellular Vesicles Are the Fastest-Growing Analyte Segment: The ctDNA segment represented 61.80% share of the global Lung Cancer Liquid Biopsy market in 2025 due to well-validated clinical data, established precedent of reimbursement, and usage in FDA approved companion diagnostic tests in targeted cancer therapy drugs. The exosomes and extracellular vesicles category is witnessing high growth due to the increasing evaluation of cell free RNA and proteins for resistance mechanisms and biomarkers.

NGS-Based Comprehensive Genomic Profiling Led Technology While Fragmentomics and Methylation Analytics Are Expanding Fastest: Comprehensive Genomic Profiling using NGS accounted for 52.70% of the market share in 2025 due to the advantage it had in simultaneously assessing numerous genes with just one blood sample test. The fastest growing segment under technologies is Fragmentomics and Methylation analytics due to their low sequencing depth needs and affordable pricing.

Therapy Selection Dominated Clinical Use While MRD and Recurrence Surveillance Are Growing Fastest: The segment contributed 40.20% to the market size in 2025 owing to its existing clinical importance in detecting actionable genomic alterations prior to initiating treatment with target therapies or immunotherapy. The MRD and recurrence detection market is witnessing fastest growth due to the accumulating clinical evidences for post-operative ctDNA analysis for recurrence risk and treatment response.

Independent Reference Laboratories Led End Users While Hospitals Are Expanding Rapidly: Reference labs formed the largest user segment with an estimated market share of 45.30% in 2025 owing to their extensive testing facilities, wide assay menus, and existing association with oncologists. Hospitals have been the fastest-growing end-user segment, with more and more academic centers and healthcare networks making investments for developing on-site sequencing facilities in order to reduce the turnaround time for molecular diagnostics tests.

North America Led the Market While Asia Pacific is Expected to Grow Fastest: North America held 43.90% share in the Global Lung Cancer Liquid Biopsy Market owing to the presence of established reimbursement policies, high density of key players, presence of clinical trial facilities, and hospital investments in sequencing technology. Asia Pacific region is expected to witness the highest regional CAGR of 15.60% in 2026 to 2035 driven by expanding reimbursement policies in China and Japan along with the growing incidences of lung cancer.

Do you have any specific queries or need any customized research on Lung Cancer Liquid Biopsy Market? Schedule a Call with Our Analyst Team: https://www.snsinsider.com/enquiry/11051

Who Should be Watching the Lung Cancer Liquid Biopsy Market?

The market is increasingly relevant across the oncology diagnostics and precision-medicine ecosystem, including:

Oncology hospitals → diagnostic laboratories → molecular testing companies → pharmaceutical manufacturers → biotechnology companies → cancer research organizations → genomic sequencing providers → healthcare payers → academic medical centers → clinical trial sponsors

The potential for commercial success among the manufacturers of liquid biopsies is wide-ranging, from ctDNA tests, exosomes, NGS, fragmentomics and MRD platforms. Among the healthcare and pharmaceutical providers, their decisions are largely affected by such factors as test accuracy, time to results, cost of reimbursement, the capability to detect mutations, and the capability to monitor disease progression and treatment effects with minimally invasive blood tests.

Precision Oncology Investment and Diagnostic Innovation Shape the 2026 Market

Commercialization in blood-based genomics for lung cancer diagnostics and therapy has been propelled by clinical research, increased health insurance and advances in technology. The market has been developing based on the use of multianalyte tests that combine ctDNA and exosomal biomarkers, MRD monitoring, and lower cost sequencing.

  • In 2025, M42, AstraZeneca and SOPHiA GENETICS launched the UAE Liquid Biopsy Initiative to advance cancer diagnosis and treatment through blood-based genomic profiling across the region.
  • In 2025, the Cancer Research Institute enrolled the first patient in the second stage of the BR.36 clinical trial, using circulating tumor DNA to assess early immunotherapy response in patients with advanced lung cancer.

Market Challenge: Analytical Sensitivity Limitations and Uneven Reimbursement Constrain Expansion

Liquid biopsy technologies still have the problem of analytical sensitivity in terms of early-stage lung cancer and individuals with low tumor burden. In such patients, it is possible that the levels of circulating tumor DNA are too low to be accurately detected, and thus the application of liquid biopsy can be limited in terms of being used independently for diagnosis, and thus making tissue biopsy necessary.

Furthermore, the market has to deal with issues related to inconsistencies in reimbursement policies across different countries and regions as well as by different insurance companies in particular. These issues relate to different coding standards and health economics requirements, which can slow down market introduction for vendors.

Buy the Lung Cancer Liquid Biopsy Market Report with Competitive Analysis at a 20% Discount: https://www.snsinsider.com/checkout/11051

Key Competitors in the Market

Companies covered in the Lung Cancer Liquid Biopsy Market research include Guardant Health, Inc., F. Hoffmann-La Roche AG (Foundation Medicine), Thermo Fisher Scientific Inc., Natera, Inc., Illumina, Inc., Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Biocept, Inc., Burning Rock Biotech Limited, Exact Sciences Corporation, GRAIL, LLC, Laboratory Corporation of America Holdings (Labcorp), Menarini Silicon Biosystems S.p.A., NeoGenomics, Inc., Personalis, Inc., QIAGEN N.V., Singlera Genomics, Inc., Tempus AI, Inc., Delfi Diagnostics, Inc., and MDxHealth SA.

CONTACT: About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

Contact Us:
Rohan Jadhav - Principal Consultant
Phone: +1-315-961-9094 (US)
Email: info@snsinsider.com